Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

[Cutaneous foreign body granulomas following cervico-facial arterial embolization: Three cases].

Gillard M, Archier E, Monnet O, Souteyrand A, Turner F, Gras R, Quiles-Tsimaratos N.

Ann Dermatol Venereol. 2018 Sep 11. pii: S0151-9638(18)30498-8. doi: 10.1016/j.annder.2018.07.008. [Epub ahead of print] French.

PMID:
30217682
2.

Elevated Stromal Inflammatory Mediators Promote Prostate Cancer Progression in African American Men.

Gillard M, Javier R, Ji Y, Zheng SL, Xu J, Brendler CB, Crawford SE, Pierce B, Vander Griend DJ, Franco OE.

Cancer Res. 2018 Sep 4. pii: canres.3810.2017. doi: 10.1158/0008-5472.CAN-17-3810. [Epub ahead of print]

PMID:
30181178
3.

Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.

Wood MD, Sands ZA, Vandenplas C, Gillard M.

Epilepsia. 2018 Sep;59(9):e147-e151. doi: 10.1111/epi.14532. Epub 2018 Aug 24.

PMID:
30144048
4.

MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Bhanvadia RR, VanOpstall C, Brechka H, Barashi NS, Gillard M, McAuley EM, Vasquez JM, Paner G, Chan WC, Andrade J, De Marzo AM, Han M, Szmulewitz RZ, Vander Griend DJ.

Clin Cancer Res. 2018 Aug 1;24(15):3668-3680. doi: 10.1158/1078-0432.CCR-17-3673. Epub 2018 May 1.

PMID:
29716922
5.

Repurposing HAMI3379 to Block GPR17 and Promote Rodent and Human Oligodendrocyte Differentiation.

Merten N, Fischer J, Simon K, Zhang L, Schröder R, Peters L, Letombe AG, Hennen S, Schrage R, Bödefeld T, Vermeiren C, Gillard M, Mohr K, Lu QR, Brüstle O, Gomeza J, Kostenis E.

Cell Chem Biol. 2018 Jun 21;25(6):775-786.e5. doi: 10.1016/j.chembiol.2018.03.012. Epub 2018 Apr 26.

PMID:
29706593
6.

Update on PARP Inhibitors in Breast Cancer.

Zimmer AS, Gillard M, Lipkowitz S, Lee JM.

Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Review.

PMID:
29644491
7.

Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients.

Gillard M, Anuset D, Maillard H, Senet P, Cuny JF, Mahe E, Sin C, Dessiner F, Goujon E, Journet-Tollhupp J, Debure C, Dabouz F, Develter T, Bernard P, Lok C, Modiano P; Members of the Groupe d'Angiodermatologie de la SFD (the Angiodermatological Group of the French Society of Dermatology).

Br J Dermatol. 2018 Jul;179(1):218-219. doi: 10.1111/bjd.16463. Epub 2018 May 15. No abstract available.

PMID:
29453858
8.

5-HT7 Receptor Antagonists with an Unprecedented Selectivity Profile.

Ates A, Burssens P, Lorthioir O, Lo Brutto P, Dehon G, Keyaerts J, Coloretti F, Lallemand B, Verbois V, Gillard M, Vermeiren C.

ChemMedChem. 2018 Apr 23;13(8):795-802. doi: 10.1002/cmdc.201800026. Epub 2018 Mar 30.

PMID:
29451954
9.

Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, Pontier A, Nguyen YTM, Maejima K, Sasaki-Oku A, Nakano K, Tanaka H, Vander Griend D, Kubo M, Ratain MJ, Miyano S, Nakagawa H.

Eur Urol Focus. 2018 Feb 1. pii: S2405-4569(18)30007-5. doi: 10.1016/j.euf.2018.01.006. [Epub ahead of print]

10.

The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.

Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade JP, Citron M, Mercier J, Hannestad J, Gillard M.

Mov Disord. 2018 Feb;33(2):273-281. doi: 10.1002/mds.27271. Epub 2017 Dec 26.

PMID:
29278274
11.

Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: Insights from the FRANCE-2 registry.

Puymirat E, Didier R, Eltchaninoff H, Lung B, Collet JP, Himbert D, Durand E, Leguerrier A, Leprince P, Fajadet J, Teiger E, Chevreul K, Lièvre M, Tchetché D, Leclercq F, Chassaing S, Le Breton H, Donzeau-Gouge P, Lefèvre T, Carrié D, Gillard M, Blanchard D.

Clin Cardiol. 2017 Dec;40(12):1316-1322. doi: 10.1002/clc.22830. Epub 2017 Dec 16.

12.

Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Gillard M, Lack J, Pontier A, Gandla D, Hatcher D, Sowalsky AG, Rodriguez-Nieves J, Vander Griend D, Paner G, VanderWeele D.

Eur Urol Focus. 2017 Dec 8. pii: S2405-4569(17)30272-9. doi: 10.1016/j.euf.2017.12.003. [Epub ahead of print]

13.

Birth of an oceanic spreading center at a magma-poor rift system.

Gillard M, Sauter D, Tugend J, Tomasi S, Epin ME, Manatschal G.

Sci Rep. 2017 Nov 8;7(1):15072. doi: 10.1038/s41598-017-15522-2.

14.

Germination and Seedling Growth of Water Primroses: A Cross Experiment between Two Invaded Ranges with Contrasting Climates.

Gillard M, Grewell BJ, Futrell CJ, Deleu C, Thiébaut G.

Front Plant Sci. 2017 Sep 26;8:1677. doi: 10.3389/fpls.2017.01677. eCollection 2017.

15.

[Amyopathic dermatomyositis (DM) with anti-MDA5 antibodies, associated with bullous pemphigoid, Sjögren syndrome and gastric MALT lymphoma].

Garcia B, Dabouz F, Pascal L, Gillard M, Modiano P.

Ann Dermatol Venereol. 2017 Oct;144(10):629-633. doi: 10.1016/j.annder.2017.05.009. Epub 2017 Jun 28. French.

PMID:
28668260
16.

Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.

Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ.

Mol Cancer Ther. 2017 Aug;16(8):1680-1692. doi: 10.1158/1535-7163.MCT-16-0923. Epub 2017 Apr 20.

17.

Strategies that facilitated expansion of a postgraduate year 1 pharmacy residency program across a community hospital-based health system.

Ticcioni A, Erdman D, Scott B, Gillard M, Cai L.

Am J Health Syst Pharm. 2017 Mar 15;74(6):375-381. doi: 10.2146/ajhp160115.

PMID:
28274979
18.

The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes.

Simon K, Merten N, Schröder R, Hennen S, Preis P, Schmitt NK, Peters L, Schrage R, Vermeiren C, Gillard M, Mohr K, Gomeza J, Kostenis E.

Mol Pharmacol. 2017 May;91(5):518-532. doi: 10.1124/mol.116.107904. Epub 2017 Mar 2. Erratum in: Mol Pharmacol. 2017 Jul;92 (1):100.

19.

Circulating tumor cells capture disease evolution in advanced prostate cancer.

Lack J, Gillard M, Cam M, Paner GP, VanderWeele DJ.

J Transl Med. 2017 Feb 23;15(1):44. doi: 10.1186/s12967-017-1138-3.

20.

Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.

Wood MD, Gillard M.

Epilepsia. 2017 Feb;58(2):255-262. doi: 10.1111/epi.13638. Epub 2016 Dec 24.

21.

Characterization of P2X4 receptor agonists and antagonists by calcium influx and radioligand binding studies.

Abdelrahman A, Namasivayam V, Hinz S, Schiedel AC, Köse M, Burton M, El-Tayeb A, Gillard M, Bajorath J, de Ryck M, Müller CE.

Biochem Pharmacol. 2017 Feb 1;125:41-54. doi: 10.1016/j.bcp.2016.11.016. Epub 2016 Nov 17.

PMID:
27867013
22.

Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.

Löscher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H.

CNS Drugs. 2016 Nov;30(11):1055-1077. Review.

23.

[(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.

Estrada S, Lubberink M, Thibblin A, Sprycha M, Buchanan T, Mestdagh N, Kenda B, Mercier J, Provins L, Gillard M, Tytgat D, Antoni G.

Nucl Med Biol. 2016 Jun;43(6):325-32. doi: 10.1016/j.nucmedbio.2016.03.004. Epub 2016 Mar 17.

PMID:
27260773
24.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B.

Epilepsia. 2016 Apr;57(4):538-48. doi: 10.1111/epi.13340. Epub 2016 Feb 26. Review.

25.

Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Reyes EE, Gillard M, Duggan R, Wroblewski K, Kregel S, Isikbay M, Kach J, Brechka H, Weele DJ, Szmulewitz RZ, Griend DJ.

J Transl Sci. 2015 Jul;1(1). pii: http://oatext.com/Molecular-analysis-of-CD133-positive-circulating-tumor-cells-from-patients-with-metastatic-castration-resistant-prostate-cancer.php. Epub 2015 Jul 30.

26.

In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.

Wood M, Ates A, Andre VM, Michel A, Barnaby R, Gillard M.

Mol Pharmacol. 2016 Feb;89(2):303-12. doi: 10.1124/mol.115.100172. Epub 2015 Dec 11.

27.

The Orphan G Protein-coupled Receptor GPR17 Negatively Regulates Oligodendrocyte Differentiation via Gαi/o and Its Downstream Effector Molecules.

Simon K, Hennen S, Merten N, Blättermann S, Gillard M, Kostenis E, Gomeza J.

J Biol Chem. 2016 Jan 8;291(2):705-18. doi: 10.1074/jbc.M115.683953. Epub 2015 Nov 30.

28.

Development of an HTRF Assay for the Detection and Characterization of Inhibitors of Catechol-O-Methyltransferase.

Kimos M, Burton M, Urbain D, Caudron D, Martini M, Famelart M, Gillard M, Barrow J, Wood M.

J Biomol Screen. 2016 Jun;21(5):490-5. doi: 10.1177/1087057115616793. Epub 2015 Nov 18.

PMID:
26582803
29.

Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue.

Gillard M, Tom WR, Antic T, Paner GP, Lingen MW, VanderWeele DJ.

Am J Transl Res. 2015 Jul 15;7(7):1227-35. eCollection 2015.

30.

Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.

Wood M, Dubois V, Scheller D, Gillard M.

Br J Pharmacol. 2015 Feb;172(4):1124-35. doi: 10.1111/bph.12988. Epub 2015 Jan 13.

31.

Intracellular trafficking pathways for nuclear delivery of plasmid DNA complexed with highly efficient endosome escape polymers.

Gillard M, Jia Z, Hou JJ, Song M, Gray PP, Munro TP, Monteiro MJ.

Biomacromolecules. 2014 Oct 13;15(10):3569-76. doi: 10.1021/bm5008376. Epub 2014 Sep 3.

PMID:
25156109
32.

Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.

Warnock GI, Aerts J, Bahri MA, Bretin F, Lemaire C, Giacomelli F, Mievis F, Mestdagh N, Buchanan T, Valade A, Mercier J, Wood M, Gillard M, Seret A, Luxen A, Salmon E, Plenevaux A.

J Nucl Med. 2014 Aug;55(8):1336-41. doi: 10.2967/jnumed.113.136143. Epub 2014 Jun 16.

33.

Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17.

Köse M, Ritter K, Thiemke K, Gillard M, Kostenis E, Müller CE.

ACS Med Chem Lett. 2014 Jan 16;5(4):326-30. doi: 10.1021/ml400399f. eCollection 2014 Apr 10.

34.

Low-grade prostate cancer diverges early from high grade and metastatic disease.

VanderWeele DJ, Brown CD, Taxy JB, Gillard M, Hatcher DM, Tom WR, Stadler WM, White KP.

Cancer Sci. 2014 Aug;105(8):1079-85. doi: 10.1111/cas.12460.

35.

Multifunctional nanoworms and nanorods through a one-step aqueous dispersion polymerization.

Jia Z, Bobrin VA, Truong NP, Gillard M, Monteiro MJ.

J Am Chem Soc. 2014 Apr 23;136(16):5824-7. doi: 10.1021/ja500092m. Epub 2014 Feb 6.

PMID:
24502768
36.

Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist.

Hennen S, Wang H, Peters L, Merten N, Simon K, Spinrath A, Blättermann S, Akkari R, Schrage R, Schröder R, Schulz D, Vermeiren C, Zimmermann K, Kehraus S, Drewke C, Pfeifer A, König GM, Mohr K, Gillard M, Müller CE, Lu QR, Gomeza J, Kostenis E.

Sci Signal. 2013 Oct 22;6(298):ra93. doi: 10.1126/scisignal.2004350.

37.

Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas.

Gillard M, Cadieu E, De Brito C, Abadie J, Vergier B, Devauchelle P, Degorce F, Dréano S, Primot A, Dorso L, Lagadic M, Galibert F, Hédan B, Galibert MD, André C.

Pigment Cell Melanoma Res. 2014 Jan;27(1):90-102. doi: 10.1111/pcmr.12170. Epub 2013 Nov 1.

PMID:
24112648
38.

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.

Daniels V, Wood M, Leclercq K, Kaminski RM, Gillard M.

Br J Pharmacol. 2013 Jul;169(5):1091-101. doi: 10.1111/bph.12192.

39.

Lead optimization of thiazolo[5,4-c]piperidines: 3-cyclobutoxy linker as a key spacer for H(3)R inverse agonists.

Provins L, Denonne F, Célanire S, Christophe B, Defays S, Delaunoy C, Delporte ML, Demaude T, Durieu V, Gillard M, Hubert D, Lamberty Y, Lorent G, Valade A, Vanbellinghen A, Van Houtvin N.

ChemMedChem. 2012 Dec;7(12):2087-92. doi: 10.1002/cmdc.201200406. Epub 2012 Oct 5.

PMID:
23042668
40.

DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and migration of melanoma cells as subunits of Elongator.

Close P, Gillard M, Ladang A, Jiang Z, Papuga J, Hawkes N, Nguyen L, Chapelle JP, Bouillenne F, Svejstrup J, Fillet M, Chariot A.

J Biol Chem. 2012 Sep 21;287(39):32535-45. Epub 2012 Aug 1.

41.

Targeting SV2A for Discovery of Antiepileptic Drugs.

Kaminski RM, Gillard M, Klitgaard H.

In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012.

42.

Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2).

Wolff C, Carrington B, Varrin-Doyer M, Vandendriessche A, Van der Perren C, Famelart M, Gillard M, Foerch P, Rogemond V, Honnorat J, Lawson A, Miller K.

CNS Neurosci Ther. 2012 Jun;18(6):493-500. doi: 10.1111/j.1755-5949.2012.00313.x.

PMID:
22672303
43.

Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes.

Scott EA, Stano A, Gillard M, Maio-Liu AC, Swartz MA, Hubbell JA.

Biomaterials. 2012 Sep;33(26):6211-9. doi: 10.1016/j.biomaterials.2012.04.060. Epub 2012 Jun 1.

PMID:
22658634
44.

Discovery of selective alpha(2C) adrenergic receptor agonists.

Jnoff E, Christophe B, Collart P, Coloretti F, Debeuckelaere A, De Ryck M, Fuks B, Genicot C, Gillard M, Guyaux M, Price N, Vandergeten MC, Vermeiren C.

ChemMedChem. 2012 Mar 5;7(3):385-90. doi: 10.1002/cmdc.201100528. Epub 2012 Jan 19. No abstract available.

PMID:
22262529
45.

Acetamide scanning around bicyclic thiazoles: SAR at the H₃ receptor.

Denonne F, Célanire S, Christophe B, Defays S, Delaunoy C, Delporte ML, Detrait E, Durieu V, Gillard M, Lamberty Y, Lorent G, Nicolas JM, Vanbellinghen A, Van Houtvin N, Provins L.

ChemMedChem. 2011 Sep 5;6(9):1559-65. doi: 10.1002/cmdc.201100248. Epub 2011 Jul 14. No abstract available.

PMID:
21761567
46.

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

Gillard M, Fuks B, Leclercq K, Matagne A.

Eur J Pharmacol. 2011 Aug 16;664(1-3):36-44. doi: 10.1016/j.ejphar.2011.04.064. Epub 2011 May 8.

PMID:
21575627
47.

A qualitative investigation of first-episode psychosis in adolescents.

Cadario E, Stanton J, Nicholls P, Crengle S, Wouldes T, Gillard M, Merry SN.

Clin Child Psychol Psychiatry. 2012 Jan;17(1):81-102. doi: 10.1177/1359104510391860. Epub 2011 Feb 24.

PMID:
21349885
48.

Training peers to provide ongoing diabetes self-management support (DSMS): results from a pilot study.

Tang TS, Funnell MM, Gillard M, Nwankwo R, Heisler M.

Patient Educ Couns. 2011 Nov;85(2):160-8. doi: 10.1016/j.pec.2010.12.013. Epub 2011 Feb 2.

49.

The development of a pilot training program for peer leaders in diabetes: process and content.

Tang TS, Funnell MM, Gillard M, Nwankwo R, Heisler M.

Diabetes Educ. 2011 Jan-Feb;37(1):67-77. doi: 10.1177/0145721710387308. Epub 2011 Jan 10.

50.

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.

Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH, Damotte D, Sautès-Fridman C, Cremer I.

J Clin Invest. 2010 Apr;120(4):1285-97. doi: 10.1172/JCI36551. Epub 2010 Mar 8.

Supplemental Content

Loading ...
Support Center